SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001628280-20-009291
Filing Date
2020-06-11
Accepted
2020-06-11 17:29:50
Documents
3
Period of Report
2020-06-10

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_159191097301956.html 3  
1 FORM 3 wf-form3_159191097301956.xml 3 4669
2 IMAGE 2 x4poaskerlj001.jpg GRAPHIC 236711
3 POWER OF ATTORNEY RSKERLJ x4poaskerlj.htm EX-24 4570
  Complete submission text file 0001628280-20-009291.txt   336913
Mailing Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139 857-529-8300
X4 Pharmaceuticals, Inc (Issuer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O X4 PHARMACEUTICALS, INC. 955 MASSACHUSETTS AVENUE, 4TH FLOOR CAMBRIGE MA 02139
Business Address
Skerlj Renato (Reporting) CIK: 0001814632 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38295 | Film No.: 20958085